The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from an androgen-dependent to an androgen-independent phenotype. One of the mechanisms of relapse is antiandrogen withdrawal phenomenon caused by mutation of 877th amino acid of androgen receptor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2004-01, Vol.64 (2), p.765-771
Hauptverfasser:	MIZOKAMI, Atsushi, KOH, Eitetsu, FUJITA, Hiroshi, MAEDA, Yuji, EGAWA, Masayuki, KOSHIDA, Kiyoshi, HONMA, Seijiro, KELLER, Evan T, NAMIKI, Mikio
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - therapeutic use Androgens - blood Androstenediol - analysis Antineoplastic agents Biological and medical sciences Cell Division - drug effects Cell Line, Tumor Dihydrotestosterone - blood DNA Primers Genes, Reporter Humans Male Medical sciences Mutation Pharmacology. Drug treatments Polymerase Chain Reaction Prostatic Hyperplasia - drug therapy Prostatic Neoplasms - chemistry Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology Receptors, Androgen - drug effects Receptors, Androgen - genetics Transfection Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!